Headlines about Catalent (NYSE:CTLT) have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.336875697622 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

Catalent (NYSE:CTLT) traded up $0.05 during midday trading on Tuesday, hitting $41.51. The stock had a trading volume of 360,178 shares, compared to its average volume of 913,073. The company has a market cap of $5,508.35, a price-to-earnings ratio of 47.71, a PEG ratio of 2.66 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. Catalent has a 12 month low of $25.51 and a 12 month high of $43.39.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. The business had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. Catalent’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.16 EPS. sell-side analysts anticipate that Catalent will post 1.46 earnings per share for the current year.

A number of research firms have recently issued reports on CTLT. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Catalent in a report on Monday, October 23rd. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 15th. Wells Fargo & Co upped their price objective on Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Finally, Bank of America reiterated a “buy” rating and issued a $45.00 price objective (up from $40.00) on shares of Catalent in a report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $44.44.

In other news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John R. Chiminski sold 181,458 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://theolympiareport.com/2017/12/26/catalent-ctlt-earning-somewhat-positive-press-coverage-report-shows.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.